Saha Sumanta, Saha Sujata, Gayen Mohan
Kalyani, India.
Department of Mathematics, Mankar College, Mankar, West Bengal India.
J Diabetes Metab Disord. 2023 Dec 30;23(1):943-966. doi: 10.1007/s40200-023-01369-0. eCollection 2024 Jun.
Although several randomized clinical trials have tested the effect of prenatal dietary supplements on plasma glucose and lipid levels in non-pharmacologically managed gestational diabetes mellitus patients (GDM), a rigorous meta-analytic compendium lacks in the context. Therefore, this study aims to address this evidence gap.
Eligible trials retrieved from searches in the PubMed, Embase, and Scopus databases were appraised using the Revised Cochrane risk-of-bias tool for randomized trials (RoB 2). The weighted mean differences (WMD) between dietary supplements and placebo were estimated using random-effect meta-analysis models for plasma glycemic and lipid markers. Meta-regression analysis ensued for effect modifier identification. The statistical significance estimation happened at < 0.05 (95% confidence interval).
This review included 19 trials (mostly Iranian and of low risk of bias primarily) of > 8000 GDM patients. Meta-analysis showed favorable effects of dietary supplementation on fasting plasma glucose (WMD: -5.42 mg/dL, p < 0.001), homeostasis model assessment indexes- insulin resistance (HOMA-IR; WMD: -1.02, p < 0.001), quantitative insulin sensitivity check index (WMD: 0.01, p < 0.001), total cholesterol (TC; WMD: -7.70 mg/dL, = 0.006), triglycerides (WMD: -10.23 mg/dL, = 0.0083), TC/high-density lipoprotein (WMD: -0.31 mg/dL, < 0.001), low-density lipoprotein (WMD: -5.79 mg/dL; < 0.001) and very-low-density lipoprotein (WMD: -5.67 mg/dL, < 0.001) levels. However, the HOMA- ß-cell function didn't increase (WMD: -17.91, < 0.001). Baseline maternal age ( = 0.28, = 0.014) and GDM diagnostic criteria ( = 0.90, = 0.012) were effect moderators of HOMA-IR and body mass index (BMI) ( = 6.07, = 0.022) and supplement type (solo versus combined) ( = 14.99, = 0.006) were effect moderators of triglyceride levels.
Altogether, antenatal dietary supplements achieved control over plasma glycemic and lipid profiles in non-pharmacologically treated GDM patients. Maternal age and GDM diagnostic criteria moderated HOMA-IR levels. BMI and supplement-type moderated triglyceride levels.
The online version contains supplementary material available at 10.1007/s40200-023-01369-0.
尽管多项随机临床试验已测试产前膳食补充剂对非药物治疗的妊娠期糖尿病患者(GDM)血糖和血脂水平的影响,但目前缺乏严谨的荟萃分析综述。因此,本研究旨在填补这一证据空白。
使用随机试验的修订版Cochrane偏倚风险工具(RoB 2)对从PubMed、Embase和Scopus数据库检索到的符合条件的试验进行评估。使用随机效应荟萃分析模型对血浆血糖和血脂标志物估计膳食补充剂与安慰剂之间的加权平均差异(WMD)。随后进行Meta回归分析以识别效应修饰因素。统计学显著性估计设定为<0.05(95%置信区间)。
本综述纳入了19项试验(主要是伊朗的试验,且主要偏倚风险较低),涉及8000多名GDM患者。荟萃分析表明,膳食补充剂对空腹血糖(WMD:-5.42mg/dL,p<0.001)、稳态模型评估指数-胰岛素抵抗(HOMA-IR;WMD:-1.02,p<0.001)、定量胰岛素敏感性检查指数(WMD:0.01,p<0.001)、总胆固醇(TC;WMD:-7.70mg/dL,p = 0.006)、甘油三酯(WMD:-10.23mg/dL,p = 0.0083)、TC/高密度脂蛋白(WMD:-0.31mg/dL,p<0.001)、低密度脂蛋白(WMD:-5.79mg/dL;p<0.001)和极低密度脂蛋白(WMD:-5.67mg/dL,p<0.001)水平有有利影响。然而,HOMA-β细胞功能并未增加(WMD:-17.91,p<0.001)。基线产妇年龄(p = 0.28,p = 0.014)和GDM诊断标准(p = 0.90,p = 0.012)是HOMA-IR的效应修饰因素,体重指数(BMI)(p = 6.07,p = 0.022)和补充剂类型(单独使用与联合使用)(p = 14.99,p = 0.006)是甘油三酯水平的效应修饰因素。
总体而言,产前膳食补充剂可控制非药物治疗的GDM患者的血浆血糖和血脂水平。产妇年龄和GDM诊断标准可调节HOMA-IR水平。BMI和补充剂类型可调节甘油三酯水平。
在线版本包含可在10.1007/s40200-023-01369-0获取的补充材料。